Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exploration of the regional effects of colchicine in the LoDoCo2 trial.
Budgeon CA, Nidorf S, Mosterd A, Fiolet A, Eikelboom J, O'Halloran S, Joyce D, Schut A, Tijssen J, Cornel JH, Murray K, Thompson P. Budgeon CA, et al. Among authors: mosterd a. Am Heart J. 2024 Dec;278:186-194. doi: 10.1016/j.ahj.2024.09.006. Epub 2024 Sep 21. Am Heart J. 2024. PMID: 39313104 Free article. Clinical Trial.
Colchicine in Patients with Chronic Coronary Disease.
Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen MWJ, Saklani P, Tan I, Thompson AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings M, Hankey GJ, Budgeon CA, Tijssen JGP, Cornel JH, Thompson PL; LoDoCo2 Trial Investigators. Nidorf SM, et al. Among authors: mosterd a. N Engl J Med. 2020 Nov 5;383(19):1838-1847. doi: 10.1056/NEJMoa2021372. Epub 2020 Aug 31. N Engl J Med. 2020. PMID: 32865380 Clinical Trial.
Efficacy and safety of low-dose digoxin in patients with heart failure. Rationale and design of the DECISION trial.
van Veldhuisen DJ, Rienstra M, Mosterd A, Alings AM, van Asselt ADJ, Bouvy ML, Tijssen JGP, Schaap J, van der Wall EE, Voors AA, Boorsma EM, Lok DJA, Crijns HJGM, Schut A, Vijver MAT, Voordes GHD, de Vos AH, Maas-Soer EL, Smit NW, Touw DJ, Samuel M, van der Meer P; DECISION Investigators and Committees. van Veldhuisen DJ, et al. Among authors: mosterd a. Eur J Heart Fail. 2024 Oct;26(10):2223-2230. doi: 10.1002/ejhf.3428. Epub 2024 Aug 30. Eur J Heart Fail. 2024. PMID: 39212246 Clinical Trial.
Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials.
Fiolet ATL, Poorthuis MHF, Opstal TSJ, Amarenco P, Boczar KE, Buysschaert I, Budgeon C, Chan NC, Cornel JH, Jolly SS, Layland J, Lemmens R, Mewton N, Nidorf SM, Pascual-Figal DA, Price C, Shah B, Tardif JC, Thompson PL, Tijssen JGP, Tsivgoulis G, Walsh C, Wang Y, Weimar C, Eikelboom JW, Mosterd A, Kelly PJ; Colchicine Cardiovascular Trialists Collaboration. Fiolet ATL, et al. Among authors: mosterd a. EClinicalMedicine. 2024 Oct 8;76:102835. doi: 10.1016/j.eclinm.2024.102835. eCollection 2024 Oct. EClinicalMedicine. 2024. PMID: 39431112 Free PMC article.
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Bhatt DL, et al. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415628 Clinical Trial.
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
Burger PM, Bhatt DL, Dorresteijn JAN, Koudstaal S, Mosterd A, Martens FMAC, Steg PG, Visseren FLJ; REDUCE-IT Investigators. Burger PM, et al. Among authors: mosterd a. Eur Heart J Cardiovasc Pharmacother. 2024 Oct 4;10(6):488-499. doi: 10.1093/ehjcvp/pvae030. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38678009 Clinical Trial.
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Ridker PM, et al. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9. N Engl J Med. 2008. PMID: 18997196 Free article. Clinical Trial.
Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.
Simpson J, Jhund PS, Silva Cardoso J, Martinez F, Mosterd A, Ramires F, Rizkala AR, Senni M, Squire I, Gong J, Lefkowitz MP, Shi VC, Desai AS, Rouleau JL, Swedberg K, Zile MR, McMurray JJV, Packer M, Solomon SD; PARADIGM-HF Investigators and Committees. Simpson J, et al. Among authors: mosterd a. J Am Coll Cardiol. 2015 Nov 10;66(19):2059-2071. doi: 10.1016/j.jacc.2015.08.878. J Am Coll Cardiol. 2015. PMID: 26541915 Free article. Clinical Trial.
180 results